Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company's pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.

Employees

Sector

Biotechnology & Medical Research

More about the company

03/08/21	Amgen's 2Q Profit Drops on Acquisition Write-off, Revenue Growth Beats Wall Street Target	DJ
19/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P TMI Index	CI
19/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Global BMI Index	CI
19/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from S&P Biotechnology Select Industry Index	CI
19/04/21	Five Prime Therapeutics, Inc.(NasdaqGM:FPRX) dropped from NASDAQ Biotechnology Index	CI
16/04/21	Five Prime Therapeutics, Inc. Announces Board Changes	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 3000 Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2000 Value Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Completeness Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell Small Cap Comp Value Index	CI
16/04/21	Five Prime Therapeutics, Inc.(NasdaqGS:FPRX) dropped from Russell 2500 Value Index	CI

09/03/21	FIVE PRIME THERAPEUTICS : Guggenheim Downgrades Five Prime Therapeutics to Neutral from Buy, Lifts PT to $38 From $29	MT
05/03/21	FIVE PRIME THERAPEUTICS : Jefferies Downgrades Five Prime Therapeutics to Hold From Buy; Price Target is $38	MT
04/03/21	FIVE PRIME THERAPEUTICS : Wells Fargo Downgrades Five Prime Therapeutics to Equal-Weight Rating From Overweight, Adjusts Price Target to $38 From $34	MT
04/03/21	FIVE PRIME THERAPEUTICS : Wedbush Cuts Five Prime Therapeutics to Neutral From Outperform on Pending Acquisition, Adjusts PT to $38 From $28	MT
11/11/20	FIVE PRIME THERAPEUTICS : SVB Leerink Adjusts Five Prime Therapeutics PT to $33 From $9, Maintains Outperform Rating	MT

05/08/22	AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS	AQ
19/04/21	Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	AQ
16/04/21	FIVE PRIME THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
16/04/21	Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	PR
16/04/21	FIVE PRIME THERAPEUTICS, INC. : Other Events (form 8-K)	AQ

04/08/21	MORNING BRIEFING - USA/Asien -2-
04/08/21	MORNING BRIEFING - Deutschland/Europa -2-
04/08/21	Les ventes d'Amgen repartent à la hausse, restent lestées par la pandémie
03/08/21	Amgens Gewinn sinkt wegen Abschreibung - Umsatz über Erwartung
27/04/21	Amgen verfehlt bei Gewinn und Umsatz in 1Q die Erwartungen

Manager	Title	Age	Since
James Bradner CEO	Chief Executive Officer	53	-
Peter Griffith DFI	Director of Finance/CFO	67	-
Jonathan Graham LAW	General Counsel	65	-

Five Prime Therapeutics, Inc. Stock

Stocks

FPRX

US33830X1046

Biotechnology & Medical Research

Latest news : Five Prime Therapeutics, Inc.

Analysts' recommendations: Five Prime Therapeutics, Inc.

Press Releases: Five Prime Therapeutics, Inc.

News in other languages: Five Prime Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Five Prime Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/04/21	David Smith	Free	Chief Financial Officer	569,947	1.2238%
16/04/21	David White	Issuer sale	Controller/Auditor	88,423	0.1899%
16/04/21	Carol Schafer	Issuer sale	Director	46,250	0.0993%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FIVE PRIME THERAPEUTICS, INC.	+0.03%	+0.16%	-	-	1.74B
ARGENX SE	-7.92%	-4.05%	+53.28%	+109.11%	57.55B
WUXI APPTEC CO., LTD.	+8.55%	+17.56%	+76.80%	+82.31%	47.08B
BIONTECH SE	-0.51%	-2.05%	-14.05%	-15.52%	22.92B
INSMED INCORPORATED	+1.56%	+5.90%	-1.55%	+423.66%	22.14B
WUXI BIOLOGICS (CAYMAN) INC.	+4.17%	+8.06%	+32.41%	-14.07%	16.33B
GENMAB A/S	-0.15%	+4.15%	+27.79%	-34.36%	15.97B
EXELIXIS, INC.	+2.58%	+1.05%	+15.90%	+172.30%	12.9B
PHARMAESSENTIA CORPORATION	+5.94%	+17.05%	+143.80%	+296.09%	12.85B
MADRIGAL PHARMACEUTICALS, INC.	+0.74%	+4.04%	+82.48%	+121.09%	11.84B
Average	+1.50%	+6.96%	+46.32%	+126.73%	24.4B
Weighted average by Cap.	+0.69%	+8.48%	+47.04%	+117.78%